Intra-arterial Y-90 Radioembolization for unresectable pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 1, interventional study assessing the safety, tolerability, and preliminary activity of selective intra-arterial Y-90 radioembolization in patients with unresectable pancreatic adenocarcinoma. Participants undergo pre-treatment SPECT/CT dose planning with 99mTc-MAA to map microsphere distribution, followed by escalating Y-90 activity in small cohorts. Post-therapy imaging and dosimetry help evaluate tumor response and organ exposure. Primary goals focus on safety and feasibility, with secondary observations of tumor response and potential clinical benefit.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed pancreatic adenocarcinoma (T4N0/1M0/1)
* ECOG performance status 0-1, for at least 2 weeks
* Life expectancy ≥12 weeks
* Signed informed consent for participation

Exclusion Criteria:

* ECOG \>2 or Karnofsky score \<60%
* Active gastrointestinal ulcers or recent GI bleeding (\<3 months)
* Active Hepatitis B/C or other significant infectious disease
* Uncontrolled cardiovascular disease (NYHA class III/IV heart failure, recent MI, severe arrhythmias)
* Significant haematological abnormalities (ANC \<1.5×10⁹/L, platelets \<100×10⁹/L, haemoglobin \<8 g/dL)
* Severe hepatic dysfunction (total bilirubin \>1.5×ULN, ALT/AST \>4×ULN without liver metastases)
* Prior solid organ transplant
* Pregnancy or lactation
* Any condition deemed by investigators as unsafe for participation

Where it's running

• Medical Radiological Research Center named after A.F. Tsyb (MRRC) - National Medical Research Center of Radiology
  Obninsk, Russia Recruiting

Study contacts

• Study coordinator: Artur Petrosian
• Email: 79533162464@yandex.ru
• Phone: +79533162464

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Microwave Ablation Feasibility for pancreatic and liver cancers guided by endoscopic ultrasound

  This study tests whether an ultrasound-guided microwave ablation device can be safely and effectively used in adults with locally advanced, unresectable, or metastatic pancreatic or liver cancers.

  Recruiting Banner Health · Gilbert, Arizona and 5 other locations · NCT07817147

• EUS-guided pancreaticobiliary procedures with the RIVOS access device

  This study tests how the RIVOS EUS access device performs during interventional procedures for pancreatic and bile duct problems in adults.

  Recruiting Orlando Health, Inc. · Orlando, Florida · NCT07696572

• SBRT plus maintenance therapy vs maintenance therapy alone in advanced pancreatic cancer

  This trial tests whether adding targeted SBRT to ongoing maintenance therapy helps people with unresectable pancreatic cancer live longer than maintenance therapy alone.

  Recruiting Phase 2 Shandong Cancer Hospital and Institute · Jinan, Shandong · NCT07600268

• New way to deliver Gemcitabine directly to pancreatic tumors in non-resectable pancreatic cancer

  This study tests a catheter-based method to deliver Gemcitabine straight into or near pancreatic tumors in locally advanced, unresectable cases.

  Recruiting Phase 1/2 Smartwise Sweden AB · Solna · NCT07575191

• Dual-target CAR-T therapy targeting mesothelin and CLDN18.2 for advanced pancreatic cancer

  This treatment will try sequential CAR‑T cell infusions that target mesothelin and CLDN18.2 in people with unresectable or metastatic pancreatic adenocarcinoma who have received prior systemic therapy.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07066995

• Ablation of unresectable pancreatic cancer with the NanoKnife irreversible electroporation system

  This study will try using the NanoKnife irreversible electroporation device to see if it is safe and can reduce pain and improve quality of life for adults with locally advanced unresectable pancreatic cancer.

  Recruiting Englewood Hospital and Medical Center · Englewood, New Jersey · NCT06937996

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.